Objectives To determine clinical and laboratorial manifestations associated with S100β protein in childhood-onset systemic lupus erythematosus (cSLE) patients Methods We included consecutive cSLE patients with disease onset before the age of 16 and healthy controls and age and healthy age and sex matched controls. All subjects underwent a standardized neuropsychological evaluation assessing the following: simple attention, complex attention, memory, visuospatial processing, language, reasoning/problem solving, psychomotor speed, and executive functions. Individual results were converted into standard scores and compared to normative data. Subjects with a total score in any of the 8 domains ≤-2 SD below the normative value were considered impaired. Mood disorders were determined through Becks Depression and Becks Anxiety Inventory (BDI and BAI) in all subjects. cSLE patients were assessed for disease activity [SLE Disease Activity Index (SLEDAI)], damage [Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)] and current drug exposures. S100β protein levels were measured by enzyme-linked immunosorbent assay using commercial kits. Clinical/laboratorial manifestations, disease activity, cumulative damage and drugs undertaken were assessed at time of blood withdrawal. Results We included 42 cSLE patients (mean age 16.56±3.68) and 20 healthy controls (mean age 19.9±5.31). Cognitive impairment was observed in 25 (60%) cSLE patients and in 3 (15%) healthy controls (p<0.05). Patients with cognitive impairment presented significantly higher levels of the S100β protein (median 38.64) compared to patients without cognitive impairment (median 25.49; p=0.001) and controls (median 23.62; p<0.001). No other clinical/laboratorial manifestations and drugs undertaken were associated to S100β protein levels in cSLE. Conclusions Cognitive impairment was associated with higher levels of the S100β protein, suggesting the presence of neuronal lesions in this cSLE patients cohort. Disclosure of Interest H. Aldar Grant/Research support from: FAPESP 2009/13046-3, A. Lapa Grant/Research support from: FAPESP 2010/13639-1, B. Belini Grant/Research support from: FAPSEP 2009/12343-4, N. Sinicato Grant/Research support from: FAPESP 2010/13637-9, M. Postal Grant/Research support from: FAPESP 2009/11076-2, P. Fernandes: None Declared, R. Marini: None Declared, S. Appenzeller Grant/Research support from: FAPESP 2008/02917-0; Conselho Nacional Pesquisa Desenvolvimento-Brasil CNPq (300447/2009-4)

Objectives To investigate the prevalence of the anti-ribosomal P (anti-P) antibodies in childhood-onset systemic lupus erythematosus patients (cSLE) and to elucidate the association between anti-P and disease activity, laboratory and treatment features in cSLE patients Methods We included consecutive SLE patients with disease onset before the age of 16 (cSLE), first-degree relatives and age and healthy age and sex matched controls. cSLE patients were assessed for disease activity [SLE Disease Activity Index (SLEDAI)], damage [Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)] and current drug exposures. Mood disorders were determined through Becks Depression and Becks Anxiety Inventory (BDI and BAI). Anti-P was measured by enzyme-linked immunosorbent assay using commercial kits. Clinical/laboratorial manifestations, disease activity, cumulative damage and drugs undertaken were assessed at time of blood withdrawal Results We included 50 cSLE patients (mean age 16.82±3.46), 35 first-degree relatives (mean age 38.73±3.89) and 20 health controls (mean age 18.3±4.97). Anti-P was present in 13 (26%) cSLE patients. No first-degree relatives or controls presented anti-P (p<0.01). The presence of anti-P was associated with anxiety on cSLE (p<0,002). No other clinical/laboratorial manifestations or treatment were associated with anti-P in cSLE. Conclusions Anti-P is frequently observed in cSLE patients and was associated with anxiety in this cohort. Grants FAPESP: 2008/02917-0; 2009/13046-3 Disclosure of Interest H. Aldar Grant/Research support from: FAPESP 2009/13046-3, A. Lapa Grant/Research support from: FAPESP 2010/13639-1, B. Belini Grant/Research support from: FAPESP 2009/12343-4, N. Sinicato Grant/Research support from: FAPESP 2010/13637-9, M. Postal Grant/Research support from: FAPESP 2009/10744-1, P. Fernandes: None Declared, L. Costallat: None Declared, R. Marini: None Declared, S. Appenzeller Grant/Research support from: FAPESP 2008/02917-0; Conselho Nacional Pesquisa Desenvolvimento-Brasil CNPq (300447/2009-4)